Drew Ranieri
Stock Analyst at Morgan Stanley
(1.19)
# 3,602
Out of 4,937 analysts
167
Total ratings
43.33%
Success rate
-12.82%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMED Globus Medical | Maintains: Overweight | $75 → $68 | $58.65 | +15.94% | 13 | Jul 15, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $4.56 | +31.72% | 4 | Mar 5, 2025 | |
| ATEC Alphatec Holdings | Assumes: Equal-Weight | $9.5 → $10 | $14.97 | -33.20% | 10 | Dec 2, 2024 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $377.58 | +17.86% | 9 | Dec 2, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $15.68 | +21.17% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $12.96 | +108.33% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $6.13 | +30.51% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $23.63 | -6.90% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $8.98 | -10.91% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $12.80 | +544.53% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $20.24 | +87.75% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $53.99 | +77.81% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $10.82 | +140.30% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $193.50 | +52.45% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $118.41 | +136.47% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $6.92 | -27.69% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $23.69 | +195.48% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $470.08 | -36.18% | 6 | Apr 25, 2022 |
Globus Medical
Jul 15, 2025
Maintains: Overweight
Price Target: $75 → $68
Current: $58.65
Upside: +15.94%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $4.56
Upside: +31.72%
Alphatec Holdings
Dec 2, 2024
Assumes: Equal-Weight
Price Target: $9.5 → $10
Current: $14.97
Upside: -33.20%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $377.58
Upside: +17.86%
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $15.68
Upside: +21.17%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $12.96
Upside: +108.33%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $6.13
Upside: +30.51%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $23.63
Upside: -6.90%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $8.98
Upside: -10.91%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $12.80
Upside: +544.53%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $20.24
Upside: +87.75%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $53.99
Upside: +77.81%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $10.82
Upside: +140.30%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $193.50
Upside: +52.45%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $118.41
Upside: +136.47%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $6.92
Upside: -27.69%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $23.69
Upside: +195.48%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $470.08
Upside: -36.18%